GSK plc (LON: GSK)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 53.86B |
| Revenue (ttm) | 31.31B |
| Net Income (ttm) | 2.51B |
| Shares Out | 4.08B |
| EPS (ttm) | 0.61 |
| PE Ratio | 21.71 |
| Forward PE | 8.21 |
| Dividend | 0.58 (4.39%) |
| Ex-Dividend Date | Nov 14, 2024 |
| Volume | 13,999,805 |
| Open | 1,308.50 |
| Previous Close | 1,322.00 |
| Day's Range | 1,302.50 - 1,323.50 |
| 52-Week Range | 1,282.50 - 1,823.50 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial StatementsNews
GSK reports mixed results from Phase 3 ovarian cancer study
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease ...
Pharmaceutical leaders convene in Paris to unveil vaccine strategies
Pfizer, Sanofi, Moderna, GSK and Novavax confirmed their attendance to Euractiv. The post Pharmaceutical leaders convene in Paris to unveil vaccine strategies appeared first on Euractiv .
European Activist Investor Bluebell Capital to Shut Hedge Fund
Bluebell Capital Partners, the European activist investment firm, is shutting down its hedge fund after targeting high-profile companies from pharmaceutical giant GSK Plc to luxury conglomerate Richem...
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouse
Shobie Ramakrishnan has helped transform GSK into a data-led company, helping speed up drug discovery.
Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline
The pharma sector showed a mixed trend during intraday trading as of 11:25 AM, with select stocks gaining while others faced selling pressure. Key Performances: Gaining Stocks: IPCA Laboratories: Up 0...
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying comp...
Boost for GSK as new bone marrow cancer drug drastically cuts risk of death in patients
The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
GSK's belantamab mafodotin reduced death risk by 42% in study
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at o...
GSK Cancer Drug Poised for Comeback After Lifting Survival Rates
A GSK Plc drug dramatically cut the risk of dying from an incurable blood cancer in a study, suggesting that the medicine withdrawn two years ago could return to market and become a blockbuster.
Final Trades: Oracle, Vertiv Holdings and GSK
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Oracle, Vertiv Holdings and GSK
The Investment Committee give you their top stocks to watch for the second half.
GSK in agreement with Muna to develop Alzheimer's therapies
GSK partners with Muna Therapeutics to develop Alzheimer's disease treatments using spatial transcriptomics. Read more here.
Duality Biologics and GSK Sign Exclusive License Agreement for ADC Drug DB-1324
Duality Biologics and GSK Sign Exclusive License Agreement for ADC Drug DB-1324
GSK, China's Zhifei Expand Shingles Shot Collaboration
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.
GSK, China's Zhifei Expand Shingles Shot Collaboration
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration
GSK said on Thursday it has expanded its agreement with China's Zhifei to explore a collaboration with the Chinese vaccines company on the British drugmaker's respiratory syncytial virus (RSV) vaccine...
GSK in agreement with Rgenta to develop RNA-targeted small molecules
European Commission approves products by BeiGene, GSK and Novartis
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK reports positive Phase 3 results for linerixibat in PBC itching
GSK share price is imploding: is it safe to buy the dip?
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October las...